20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
ArriVent BioPharma, Inc. Common Stock (AVBP) operates in the BIOTECHNOLOGY industry and is headquartered in Newtown Square, United States with about 77 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-09-30, AVBP reported $0M in revenue and ($166M) in net income.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($176M) | ($178M) | ($94M) | ($75M) | ($37M) | ($9M) |
| Operating Margin % | — | — | — | — | — | — |
| Net Income | ($164M) | ($166M) | ($80M) | ($69M) | ($37M) | ($52M) |
| Net Margin % | — | — | — | — | — | — |
| EBITDA | ($164M) | ($166M) | ($80M) | ($69M) | ($37M) | ($52M) |
| Earnings Per Share (EPS) | $-3.77 | $-4.32 | $-2.56 | $-2.17 | $-1.10 | $-40.44 |
| Shares Outstanding (M) | 48M | 38M | 31M | 32M | 33M | 1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($53M) | ($46M) | ($39M) | ($38M) | ($34M) | ($67M) | ($24M) | ($24M) |
| Operating Margin % | — | — | — | — | — | — | — | — |
| Net Income | ($50M) | ($43M) | ($36M) | ($35M) | ($31M) | ($64M) | ($21M) | ($21M) |
| Net Margin % | — | — | — | — | — | — | — | — |
| EBITDA | ($50M) | ($43M) | ($36M) | ($35M) | ($31M) | ($64M) | ($21M) | ($21M) |
| Earnings Per Share (EPS) | $-1.05 | $-0.96 | $-0.92 | $-0.83 | $-0.90 | $-1.90 | $-0.61 | $-0.61 |
| Shares Outstanding (M) | 48M | 45M | 38M | 42M | 35M | 34M | 34M | 34M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($148M) | ($161M) | ($70M) | ($56M) | ($44M) | ($13M) |
| Free Cash Flow (FCF) | ($148M) | ($161M) | ($70M) | ($56M) | ($44M) | ($13M) |
| FCF Margin % | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($40M) | ($42M) | ($31M) | ($36M) | ($26M) | ($68M) | ($16M) | ($16M) |
| Free Cash Flow (FCF) | ($40M) | ($42M) | ($31M) | ($36M) | ($26M) | ($68M) | ($16M) | ($16M) |
| FCF Margin % | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Total Assets | $395M | $333M | $275M | $163M | $183M | $43M |
| Cash & Cash Equivalents | $155M | $46M | $74M | $150M | $163M | $37M |
| Total Liabilities | $28M | $26M | $17M | $12M | $8M | $2M |
| Total Debt (Short + Long-Term) | $0M | $0M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $367M | $307M | $258M | $151M | $174M | $41M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AVBP viewer.
About TickerBase · Data methodology & sources · Privacy · Terms